University of Connecticut, Department of Pharmaceutical Sciences, 69 N. Eagleville Road, Storrs, CT 06269, United States.
Biochem Pharmacol. 2019 Oct;168:269-274. doi: 10.1016/j.bcp.2019.07.012. Epub 2019 Jul 12.
Identifying novel therapeutics for the treatment of substance use disorder (SUD) is an area of intensive investigation. Prior strategies that have attempted to modify one or a few neurotransmitter receptors have had limited success, and currently there are no FDA-approved medications for the treatment of cocaine, methamphetamine, and marijuana use disorders. Because drugs of abuse are known to alter the expression of numerous genes in reward-related brain regions, epigenetic-based therapies have emerged as intriguing targets for therapeutic innovation. Here, I evaluate potential therapeutic approaches and challenges in targeting epigenetic factors for the treatment of SUD and highlight examples of promising strategies and future directions.
针对物质使用障碍(SUD)的治疗方法的研究一直以来都是热点。先前的策略试图通过改变一个或几个神经递质受体来实现,但收效甚微,目前FDA 也没有批准任何药物用于治疗可卡因、冰毒和大麻使用障碍。由于众所周知,滥用药物会改变与奖励相关的大脑区域中许多基因的表达,基于表观遗传的治疗方法已成为治疗创新的一个有趣目标。在这里,我评估了针对 SUD 治疗的表观遗传因素的潜在治疗方法和挑战,并强调了一些有前途的策略和未来方向。